One of the most important diagnostic tools used to detect prostate cancer is prostate-specific antigen (PSA), yet increased PSA alone does not reflect the presence of prostate cancer. Other pathological prostatic conditions such as prostatitis and benign prostatic hyperplasia (BPH) may also increase the level of PSA. However, unlike in other prostate diseases, PSA has a key role in the diagnosis and management of prostate cancer. The incidence of prostate cancer varies from country to country, with the highest incidence being found in the Western world and the lowest in Asian countries. Owing to the low incidence of prostate cancer, there could be different views regarding the use of PSA in Asian countries, especially for the early detection/screening of prostate cancer. The purpose of this article is to review the use and value of PSA in the diagnosis of prostate diseases (especially prostate cancer) in Asian countries/populations. A literature search was performed in 'MEDLINE' (PubMed) and Google Scholar using main keywords such as 'PSA', 'PSA usage', 'PSA sensitivity and specificity', 'Asia', and various countries in Asia. Articles that provide population/community-based PSA data, together with the characteristics, distribution, and indications for PSA testing in the respective countries, were selected. Eleven papers were finally selected for inclusion in this review. Five studies found that PSA, by its 95th percentile value, have an age-referenced tendency in Asian males, similarly to the West. The predictive values of PSA in detecting prostate cancer are also quite similar to those in Western countries. With the exponential growth of the aging population in the world, especially in Asia, the incidence of prostate cancer will follow this upward trend. Therefore, PSA testing for screening or diagnostic purposes would increase with time in Asia.
Introduction
Prostate cancer (PCa) is the most common malignancy in males and the second leading cause of male cancer death in the US [Jemal et al. 2009 ]. The incidence of PCa varies from country to country, with the highest incidence being found in the Western world and the lowest in Asian countries [Ferlay et al. 2004 ]. According to GLOBOCAN 2002, a global epidemiological study, the incidence of PCa in Asian countries is much lower than those in Western countries [Ferlay et al. 2004 ]. Among South East Asian countries, Indonesia supposedly has the highest incidence. Also, there is a difference in the prevalence and the rate of disease per 100,000 population between races, where once again the Asian/Pacific Islander race group in the US has the lowest prevalence (0.7871%) compared with Blacks (2.2927%), who had the highest prevalence, followed by Whites (1.5071%) [Horner et al. 2008 ]. In part, this could be related to the specific dietary habits of each group. There are studies that have shown that a lower intake of red meat and a higher intake of soya-based food may reduce the risk of PCa [Shirai et al. 2002; Giovanucci et al. 1993] .
In Indonesia, based on data from Cipto Mangunkusumo Hospital (CMH) and the Dharmais Cancer Center (DCC), the incidence and prevalence of PCa have increased by a factor of 2.5 from 1995 to 2004 [Umbas, 2005] .
One of the most important diagnostic tools used to detect PCa is prostate-specific antigen (PSA). PSA has been used as a tumor marker for malignancy of the prostate since the late 1980s. However, increased PSA alone does not reflect the presence of PCa. Other pathological prostatic conditions such as prostatitis and benign prostatic hyperplasia (BPH) may also increase the level of PSA. The incidence and prevalence of prostatitis and BPH in Asian countries seems to be comparable to Western countries, but this does not hold for PCa [Homma et al. 1997 ]. However, unlike in other prostate diseases, PSA has a key role in the diagnosis and management of PCa.
Therefore, owing to the low incidence of PCa, there could be different views regarding the use of PSA in Asian countries, especially for the early detection/screening of PCa.
Purpose
The purpose of this article is to review the use and value of PSA for the screening of PCa in Asian countries/populations.
Methods
A literature search was performed in 'MEDLINE' (PubMed) and Google Scholar using main keywords such as 'PSA', 'PSA usage', 'PSA sensitivity and specificity', 'Asia', 'Indonesia', 'Japan', 'Thailand', 'Korea', 'India', 'Pakistan', and other countries in Asia. We also searched epidemiological data from existing national and world health registries. For selection in this review, the article has to provide population/communitybased PSA data, together with the characteristics, distribution, and indications for PSA testing in the respective countries. Papers which do not provide (statistical) data (sensitivity, specificity, predictive values, and/or the use of PSA for screening purpose) are excluded. The data are extracted and then compiled in a database and put in tables.
Results
The complete literature search produced 259 papers, originating from various Asian countries such as Thailand, Korea, India, Japan, Singapore, Indonesia and from Western (USA, Canada, and European) countries. After carefully examining the papers, only 11 papers were finally selected for inclusion in this review. PSA levels (shown as the 95th percentile values) in various (five) Asian countries are reflected in Table 1 , stratified by age groups [Liu et al. 2008; Malati and Kumari, 2004; Lee et al. 2000; Saw and Aw, 2000; Oesterling et al. 1995] .
The other six studies showed the predictive values and/or detection rate for PCa using PSA ranges. The PSA ranges examined were mainly <20.0 ng/ ml as seen in Table 2 [Ishidoya et al. 2008; Lee et al. 2006; Safarinejad, 2006; Gao et al. 2005; Wu and Huang, 2004; Wiwanitkit, 2004] .
Discussion
PSA has been widely used as an initial diagnostic procedure mainly in patients with lower urinary tract symptoms (LUTS). In these patients PSA is examined to screen for the possibility of PCa.
PSA association with age PSA is widely known to be associated with age. Table 1 clearly shows that this is also the case in various Asian populations [Liu et al. 2008; Malati and Kumari, 2004; Lee et al. 2000; Saw and Aw, 2000; Oesterling et al. 1995] . In the Chinese, Korean, Japanese, and Indian ethnic groups, the increase in PSA 95th percentile value correlates with increasing age group. A mass screening study in Changchun, China, [Gao et al. 2005 ] also concluded that the increasing value of PSA corresponds to an increase in age and detection rate of PCa. Therefore, agereferenced PSA values should also be applicable in the Asian population.
PSA value across Asian ethnic groups
At least one study has evaluated the serum PSA value in various ethnic groups. Based on a community-based study in Singapore, Chia and colleagues concluded that the median PSA level in the Chinese, Malay and Indian ethnic groups in Singapore were not different, were positively associated with age, and were lower than the PSA levels of the White population in the USA [2007] .
Diagnostic value of PSA Based on a meta-analysis of 4 studies in Thailand, the overall prevalence of PCa was 10.8% (143/1321), with overall sensitivity, specificity, false-positive and false-negative rates of PSA equal to 95.8%, 66.2%, 33.8% and 4.2%, respectively, and can be used for screening purposes [Wiwanitkit, 2004] . In this country, PSA is also useful to cover those patients who do not want a digital rectal examination (DRE) due to its demeaning nature according to local customs.
In another Asian country such as India, they concluded that there is no scientific rationale to advocate routine use of PSA for early detection of PCa in Indian males due to the low incidence of PCa and the still doubtful utility of screening in populations with a high incidence of PCa [Dubey, 2009] .
Based on a community-based study of PSA levels in Singapore, they proposed it might be more appropriate to offer PSA testing to men who are >60 years old rather than the current recommendation of >50 years old [Chia et al. 2007 ]. In one study in ethnic Chinese, the PSA test sensitivity at the traditional cutoff (4.0 ng/ml) was 96% (specificity ¼ 14%) and with the use of 90% sensitivity, if the PSA cutoff for Chinese was 6.0 ng/ml (specificity ¼ 36%), it might avoid 162 (13.1%) biopsies, but 4 (1.6%) cancers would have been overlooked [Wu and Huang, 2004] .
The present study reveals that PSA alone can be used efficiently as a first-line test and as a repeat screening test for PCa. Based on a study in Iran, among the screened men, 433 of 3670 (11.8%) had a serum PSA concentration 2.1 ng/ml and 128 PCas were diagnosed (positive predictive value [PPV] 29.6%) at screening [Safarinejad, 2006] .
In our center, it is also recommended to perform PSA tests for men over 50 years old. Between 1994 and 2005, there were 385 PCa patients found in our center, and there were 21 (6.3%) patients with their PSA lower than 4 ng/ml. Most of the cancers are confirmed by biopsy of the prostate [Umbas, 2005] .
In the Western world, the reliable cut-off value of PSA is in debate: a PSA level more than 4.0 ng/ml was stated as abnormal and it is recommended to perform prostatic biopsies, but present studies reported that a cut-off point below 4 ng/ml would also produce a high PPV. Schrö der and colleagues reported that the PPV for finding cancer on prostate biopsy with a PSA level between 2.6 and 4.0 ng/ml was 20%, and 50% of the cancers detected at a PSA level of less than 4.0 ng/ml were high-grade cancers [Schrö der et al. 1998 ]. Gilbert and colleagues also suggested the cut-off point to be lowered to 2.5 ng/ml because of the similar detection rate of PCa between PSA levels of 2.54.0 ng/ml (27.48%) and PSA levels of 4.010 ng/ml (30.08%) [Gilbert et al. 2005] . Another study performed by Saito in a Japanese population also stated that the PSA cut-off point of 2.5 ng/ ml would increase the detection of localized PCa, especially T1c and it is recommended to perform [Saito, 2007] .
Between 1995 and 2001, a large study in a single center in St Louis, USA, screened 6691 men for PCa using PSA. The study showed that the diagnostic performance of total PSA using a threshold of 2.6 ng/ml is better. It would double the cancerdetection rate from 18% to 36%. The results also indicated that if biopsies were performed onlywhen the PSA was higher than 4 ng/ml, then 82% and 65% of cancers in men below 60 years of age and over 60 years of age, respectively, would be missed [Punglia et al. 2003 ].
PSA derivatives
It can be concluded that the role of PSA in clinical staging is restricted. Various adjustments, such as the ratio of free-to-total (f/t) PSA, PSA density (PSAD) or blood-based molecular diagnostics, have, therefore, been attempted to improve the diagnostic value of PSA. There were many trials to see whether PSA derivatives such as f/tPSA, PSAD and PSA velocity (PSAV), can improve the diagnostic value of PSA and to avoid unnecessary biopsies. Thakur and colleagues concluded that f/tPSA could be used to increase the sensitivity of the test and reduce the number of unnecessary biopsies in patients having serum total PSA concentration in the range of 220 ng/ml, combined with DRE and transrectal ultrasound (TRUS) [Thakur et al. 2004 ].
Another diagnostic tool used to enhance the accuracy of PCa screening is PSAV. Based on research performed by Ito and colleagues, the accuracy of screening improved with PPV rose up to 15.7%, and similar improvements were seen with sensitivity and specificity, which rose up to 48.6% and 97.7% for PSA 2.0-4.0 ng/ml [Ito et al. 2002] .
Complexed PSA (cPSA) has also been suggested to be a superior initial test in the detection of PCa in Japan. In one study performed by Okihara and coworkers, at 90% sensitivity, the specificity of cPSA improved by 6.1% compared with total PSA (tPSA) [Okihara et al. 2006 ]. In the West, cPSA was also studied by Froehner and colleagues, and they concluded that there was a statistically significant advantage for cPSA compared with tPSA in differentiating BPH and PCa but small and questionable in its clinical relevance [Froehner et al. 2006 ].
Ultimately, end people feel more comfortable with tPSA testing alone, as stated by Safarinejad and colleagues, and based on their study PSA alone can be used efficiently as a first-line test and as a repeat screening test for PCa. PSA levels >2.1 ng/ml deserve prostatic biopsy, most likely because DRE is insensitive both at high and at low tPSA levels and TRUS does not increase the sensitivity, as only 39.1% of cancers were visible on TRUS and 25.8% were both impalpable and invisible [2006] .
Mass screening
Whether or not to perform mass screening is still a controversial issue; nonetheless, the PSA test is commonly ordered by physicians around the world. If screening is requested by an asymptomatic man, the clinician should inform him of all of the benefits and risks associated with the test including DRE and biopsy, and based on his understanding, the patient can determine whether the test would be appropriate.
From a large, randomized, multicenter trial in Europe, the European Randomized Study of Screening for Prostate Cancer (ERSCP Study), PSA screening was associated with a significant reduction of 29% in the absolute risk of PCa death after a median follow up of 9.0 years. However, this also means that 1410 men would need to be screened and 48 additional cases of PCa would need to be treated to prevent one death from PCa. This number presumably would be greater in the Asian setting. The benefit of screening was restricted to the core age group of subjects who were between the ages of 55 and 69 years at the time of randomization [Schrö der et al. 2009 ].
In Asian countries, due to the different PSA detection rate and socioeconomic values, the use of mass screening might not be an option. Among populations with low incidence of PCa such as the Chinese, minimizing unnecessary biopsies might be a more important issue than maximizing the cancer detection rate [Wu and Huang, 2004] .
In Indonesia, we need more evidence to recommend mass screening with PSA. The number of PCa cases, although steadily increasing, has not yet reached a level of general public health importance. However, there is increasing awareness in the general public, especially in those who routinely do complete regular medical check ups, to perform routine PSA testing. What we could and have done is to promote the use of PSA in many institutions as indicated in patients with LUTS and cancer in another organ in men more than 50 years old.
International guidelines to screen PSA routinely are changing overtime. The American Cancer Society and American Urological Association recommend an annual PSA test for asymptomatic men above the age of 50 years [Smith et al. 2007; American Urological Association, 2000] .
In contrast, The American College of Preventive Medicine [Ferrini and Woolf, 2008] and the US Preventive Services Task Force [Harris and Lohr, 2008] conclude that there is an insufficient evidence to recommend routine population screening with DRE or PSA. The National Health Service of the United Kingdom does not recommend screening even though the burden of PCa is significant in that country [Weston and Parr, 2003 ]. However, there is also a general agreement among clinicians that PSA testing has the highest predictive value for PCa as compared with DRE or TRUS alone, and PSA testing remains as the initial procedure performed to screen for PCa [Mistry and Cable, 2003 ].
This review is limited in that there is always a possibility of not obtaining the most accurate or complete data. Although some Asian countries are well developed, many do not have established national registries. Many data, such as the data from our institution, is hospital-based and may not represent the situation in the general population. Nevertheless, the studies cited in this review provide a reflection of the use and value of PSA in many parts of Asia.
The lower incidence of PCa in Asia does not make people, physicians and patients alike, undervalue PSA testing. The awareness of PSA testing has risen and will continue to rise still further. In medical checkups and laboratory testing, especially in elderly males, PSA testing is now quite common. Whether this will produce an increase in PCa detection, only time will tell. According to an estimation of the world's population growth, many Asian countries have the fastest growing aging population in the world. The proportion of the population older than 65 years old in these countries will surge nearly fourfold from 2000 until 2050 [Lunenfeld, 2002] . With this in mind it can only be true that PSA will soon reach an important place in healthcare management in Asia.
Conclusions
Despite the low incidence of PCa in Asian races, PSA testing is still one of the best tools to provide information for the diagnosis of PCa. As in Western countries, PSA testing proved to be suitable for clinical use in the Asian setting. The need for local guidelines and standardization for mass screening is increasing, owing to the differences in the value of PSA between races and countries. This problem could only be solved by improving national registries and conducting more research.
In the meantime, what we could do is to recommend and promote PSA testing in Asian elderly males, especially in those above 50 years old.
